Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02766543 · ClinicalTrials.gov registry record · NA

Pivotal Study of MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer

A NA study of Prostate Cancer, sponsored by Profound Medical.

Active
Registry status
NA
Development phase
150
Enrollment target
14
Study locations

NCT02766543 is a NA study of Prostate Cancer that is active but no longer recruiting, run by Profound Medical. The registered enrollment target is 150 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (75% lower). The trial reports 14 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02766543, a NA study of Prostate Cancer, is active but no longer recruiting, sponsored by Profound Medical.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
150 participants
Enrollment target
14
Study locations

Study Summary

A prospective, multi-center, single-arm study, planned in 150 patients. The primary objective of the study is to further evaluate the safety and efficacy of a magnetic resonance imaging (MRI)-guided transurethral ultrasound therapy system (TULSA-PRO) intended to ablate prostate tissue of patients with localized, organ-confined prostate cancer.

Conditions Studied

Prostate Cancer

Interventions

  • DEVICE MRI-guided Transurethral Ultrasound Ablation

Study Locations (14)

Other

  • University Hospital of Cologne - Cologne
  • Universitätsklinikum Heidelberg (University of Heidelberg, Dept of Urology) - Heidelberg
  • Radboud University Medical Center - Nijmegen
  • ResoFus Alomar (Hospital Universitari De Bellvitge) - Barcelona

Ontario

  • London Health Sciences Centre - London
  • Sunnybrook Health Sciences Centre - Toronto

California

  • University of California Los Angeles - Los Angeles

Connecticut

  • Yale Cancer Centre - New Haven

Illinois

  • University of Chicago - Chicago

Indiana

  • Indiana University - Indianapolis

Maryland

  • Johns Hopkins Medicine - Baltimore

Michigan

  • William Beaumont Hospital - Royal Oak

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2016-09-21
Est. Completion 2028-09-30
Phase NA

Sponsor

Profound Medical

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02766543

The ClinicalTrials.gov registry entry for NCT02766543 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (75% lower). The listed sponsor is Profound Medical, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which MRI-guided Transurethral Ultrasound Ablation is the first listed.

NCT02766543 reports 14 study locations spanning 10 distinct geographic areas - top geographies include Other, Ontario, California.

Frequently Asked Questions

What is clinical trial NCT02766543 about?

NCT02766543 is a clinical study titled "Pivotal Study of MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer". A prospective, multi-center, single-arm study, planned in 150 patients. The primary objective of the study is to further evaluate the safety and efficacy of a magnetic resonance imaging (MRI)-guided transurethral ultrasound therapy system (TULSA-PRO) intended to ablate prostate tissue of patients wi...

What is the current status of trial NCT02766543?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2016-09-21. Estimated completion is 2028-09-30.

What conditions does trial NCT02766543 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT02766543?

The interventions under investigation include: MRI-guided Transurethral Ultrasound Ablation (DEVICE).

Who is sponsoring clinical trial NCT02766543?

This trial is sponsored by Profound Medical, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02766543 being conducted?

This trial has 14 study locations across California, Connecticut, Illinois, Indiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.